Introduction
The World Health Organization estimates that depression will be the second leading cause of global illness by 2020. Severe depression may significantly decrease quality of life and lead to death by suicide, for which the risk rate is 6% to 15% among patients with this affective disorder. It may also increase mortality associated with general medical conditions, most notably cardiovascular disease. 1 More than 60 years after the introduction and use of modern psychopharmacology, electroconvulsive therapy (ECT) continues to be an essential therapeutic modality in the treatment of mental illnesses. The effectiveness of ECT in treating depression has been demonstrated in numerous studies conducted over the past decades. 2 The use of pharmacologically induced seizures to treat mental illness was first described by Laszlo Meduna in 1934, but it was only in 1938 that Ugo Cerletti and Lucio Bini used an electric current, or electroshock, for the treatment of patients with depression. 3 ECT has been associated with the beginning of modern biological psychiatry.
Research has improved ECT efficacy and safety and None of these techniques proved to be superior to ECT in terms of action time and response rates. Although ECT is the oldest surviving biological therapy in psychiatry and the most effective short-term treatment for major depression, it still faces constant skepticism. 4 The precise mechanism of ECT action remains unknown, and the greatest difficulty in understanding ECT function lies in the induction of a generalized seizure by an electric current that passes through the brain. It is associated with multiple sequences of biochemical and neuroendocrine changes, which are very difficult to isolate. It is also difficult to assign treatment results to a single specific therapeutic effect. ; and type 2, or low-affinity glucocorticoid receptor (GR). 7 Glucocorticoids interact with their receptors in multiple target tissues, including the HPA axis, and are 15 Acute ECT has been consistently associated with improvement in plasma levels of cortisol. [16] [17] [18] [19] Studies have found that the levels of cortisol and ACTH measured Individuals in the control group, recruited among hospital employees, were matched for sex and age.
Peripheral blood was collected from the upper limb to measure morning cortisol levels, and the BDI was administered. Individuals were excluded if they scored more than 10 points in BDI, or had clinical psychiatric comorbidities or neuroendocrinologic conditions that might affect the HPA axis.
In the group of patients with depression, cortisol was measured during the morning after awakening, and the BDI scale was applied at three time points 
Results
In the statistical analysis of the results, a chi-square test was used to evaluate the association between categorical variables and quantitative variables.
The Kolgomorov-Smirnov test was used to check (Table 1) .
Eleven participants completed the study and had baseline and post-ECT results. Seven were women, there were no differences in sex and age distribution.
Mean age was 59.5±10.93 years, mean baseline cortisol level was 16.36±5.065 µg/dL, and mean BDI score was 44.82±8.424 (Table 1 ).
The comparison of the results of the group of patients with depression and of the control group revealed that initially only sex and age were the same between groups, whereas BDI scores and baseline cortisol levels were significantly different: p = 0.008 for baseline cortisol level and p < 0.001 for BDI scores. In the seventh and final ECT session, the groups had similar cortisol levels (p ≥ 0.05), whereas BDI scores remained different at the three time points, but decreased progressively towards the values found for the control group (p = 0.01) (Figure 1 ).
Mean age in the control group was 54.10±12.324, the cortisol level at the first ECT session, the greater the difference in BDI scores between the first and the seventh ECT sessions (Table 2) .
BDI scores decreased progressively and were significantly different at the three time points (p = 0.003).
Some variables were correlated, and findings of the comparisons between age and cortisol variation from the beginning to the end of the treatment with ECT were significant.
The older the patient, the greater the difference between cortisol levels at the first and the last ECT session; the higher the BDI scores at the first time point, the greater the cortisol level. There was also a correlation between baseline cortisol levels and BDI score differences at the first and the seventh session.
The comparison of the depressed and control groups revealed that only sex and age at baseline were the same between groups, whereas BDI scores and baseline cortisol levels were significantly different (baseline cortisol: p = 0.008; BDI: p < 0.001). At the seventh and at the final ECT sessions, the groups had similar cortisol levels (p ≥ 0.05), whereas BDI scores remained different between groups at the three different time points, but there was a progressive reduction towards levels in the control group (p = 0.01) (Figure 3 ).
In the depressed group, there were no significant differences between age and sex distribution. Zis et al. 28 compared cortisol and prolactin levels in 10 patients with depression treated with unilateral ECT using high and low voltage. They found that seizure duration did not affect cortisol and prolactin levels, but cortisol levels were significantly higher in the high voltage subgroup than in the low voltage group. Ozsoy et al. 40 examined blood samples collected two days before, 10 minutes after the first session and three days after the end of ECT from patients with depression, and compared findings with the results of a blood sample collected from individuals in the control group. They found that baseline cortisol levels did not differ significantly between patients and controls, but that cortisol levels were significantly lower in the group of patients after ECT completion.
Acute treatment with ECT affected ACTH, cortisol, and prolactin levels, which suggests that the ECT regulates serum levels of the hormones of the HPA axis by stimulating the hypothalamus to function normally. 18, 37, 41 In this study we investigated the changes in plasma cortisol levels throughout ECT treatments and analyzed BDI scores. Cortisol levels decreased as ECT treatment progressed. Cortisol levels were greater than those of the control group at baseline, but at the 7th ECT session, cortisol levels were similar to those of the control group.
Values were significantly greater in the group of patients older than 60 years than among individuals in the control group. There were no statistically significant differences between men and women 60 years or older in the depressed group. Reductions of cortisol levels after ECT specifically in elderly patients with depression are not a frequent finding in the literature.
According to Keller et al., 36 high cortisol levels are found in depression, and levels are higher in psychotic depression. There is evidence that this is associated with age, and elderly individuals with depression tend to have higher cortisol levels. Physiological aging is associated with a relative increase in the activity of the HPA axis, associated with a reduction of mineralocorticoid and glucocorticoid receptors. Sapolsky et al. 42, 43 found consistent evidence that the rupture of glucocorticoid levels resulted in mood and cognition disorders, neurophysiological changes, alterations in the activity of neurotransmitters and neuroanatomic variations.
Discussion
Neuroendocrine studies have found variations in cortisol levels and changes in the hypothalamichypophysis-adrenal axis of patients with depression. [28] [29] [30] [31] [32] Although these biological changes are some of the wellestablished theses in psychiatry, their psychopathological and physiological implications are still unclear.
Abrams & Taylor, 33 Fink & Nemeroff 34 and Grover et al. 3 suggested that ECT corrects a deregulation of neuropeptides by means of diencephalic stimulation. They found an increased production and release of several Keller et al. 36 reported that the patients with depression who attempt suicide violently have higher cortisol levels than patients with depression and non-violent suicide attempts, and suggested that deregulation of the HPA axis may be a factor of violent suicide behavior. Cortisol levels are higher in brain spinal fluid, but return to normal after treatment and recovery from depression. 37 Markianos et al. 38 studied a group of 13 control individuals and 11 men with depression undergoing eight to 13 ECT sessions and their variation of cortisol levels.
Baseline cortisol levels were 30% greater in patients than in controls, but there were no differences from baseline levels after ECT sessions are consistent with the findings reported by Aperia et al., 16 Aperia et al., 20 Weizman et al. 23 and Ozsoy et al. 40 Ozsoy et al. 40 suggested that the mechanism of action of ECT might be explained by the fact that it changes the instability of levels of neuroactive steroids that affect gamma-aminobutyric acid (GABA)
antagonists, such as dehydroepiandrosterone (DHEAS), and GABA agonists, as testosterone and progesterone.
In depression, estrogen and testosterone levels are physiological unstable, which contributes to the symptoms of depression, such as sexual dysfunction and reduced energy. Moreover, ECT might contribute to clinical improvement by means of regular activation of neuroactive steroids. In their study, high DHEAS levels were detected in male patients with depression, whereas no changes were found in women. After ECT, DHEAS elevations were less marked in men and remained stable in women, which indicated an inverse correlation between DHEAS and cortisol levels after ECT. These data are consistent with the findings in our study, in which cortisol levels differed between male and female patients after treatment with ECT.
We believe that glucocorticoid receptors in elderly populations with depression are disrupted and that ECT may reestablish the function of the HPA axis.
Cortisol levels decrease during treatments using ECT, which suggests that ECT acts as a regulator of the HPA axis. It remains uncertain, however, whether hypercortisolism is an epiphenomenon or a direct contribution to depressive symptoms and biochemical changes in major depression.
The evaluation of our results should take into consideration study limitations, and our findings should be classified as preliminary. The association of depression severity with hypercortisolism mechanisms is not warranted for several reasons. First, our sample size was too small to establish a correlation between depression severity, cortisol levels and possible changes of the hippocampal volume. Second, cortisol levels in elderly populations were not analyzed because our sample of patients 60 years or older was small. 
